Gina Mauro

The incorporation of palliative care specific to mental health services and therapy remains underutilized in the care of patients with pancreatic cancer.

The FDA has approved revumenib (Revuforj) for the treatment of patients with relapsed/refractory acute leukemia with a KMT2A translocation in adult and pediatric patients 1 year and older.

James R. Berenson, MD, discusses serum BCMA and markers for predicting outcomes and monitoring disease in patients with multiple myeloma.

Ginger J. Gardner, MD, FACOG, walked through the strides of gynecologic cancer research and emphasized the efforts that still need to be accomplished.

Concurrent chemoradiation yielded similar contralateral breast recurrence outcomes vs a sequential approach in early-stage breast cancer.

Experimental regimens did not cross the threshold to show superiority vs standard cisplatin plus 70 Gy radiation in those with HPV-associated oropharynx cancer.

The FDA granted traditional approval to selpercatinib for patients with advanced or metastatic medullary thyroid cancer with a RET mutation.

Pluta Cancer Center clinicians discussed how to improve sexual health outcomes for patients diagnosed with gynecological cancer.

The addition of pembrolizumab to chemotherapy with or without radiation did not improve DFS across the intent-to-treat population of KEYNOTE-B21.

Updated findings from the AEGEAN trial support perioperative durvalumab as a new therapy option for those with resectable non–small cell lung cancer.

The addition of neoadjuvant S-1 also reduced the risk of death compared with adjuvant therapy alone in the phase 3 PRODIGY trial.

Targeting multiple survival pathways simultaneously with ViPOR may be effective in specific molecular subtypes of relapsed/refractory DLBCL.

Adding metastasis-free directed radiation to chemotherapy more than tripled progression-free survival vs chemotherapy alone in the EXTEND trial.

Cyclophosphamide-based prophylaxis for GVHD showed similar outcomes across racial subgroups regardless of matched or mismatched unrelated donors.

Frontline zolbetuximab plus chemotherapy is one step closer to approval by the European Commission for select patients with advanced gastric/GEJ cancer.

After allogeneic hematopoietic cell transplantation, pregnancies could be carried out and were successful.

SLS009 is a highly selective CDK9 inhibitor that is being studied in an ongoing phase 1/2 trial for patients with hematologic malignancies.

“This is currently the largest pooled safety dataset for a HIF-2α inhibitor we need to be familiar with,” lead study author Toni K. Choueiri, MD.

Investigators evaluated the impact of low-molecular weight heparin after the first 60 days of treatment as well as treatment overall.

Investigators will assess the clinical activity, safety, and pharmacokinetics of GTB-3650 among those with CD33-expressing cancers in a phase 1 trial.

Frontline acalabrutinib plus bendamustine/rituximab may become a new standard therapy in MCL, according to Michael Wang, MD.

The novel antibiotic lock solution Mino-Lok could help treat catheter-related infections that patients with cancer may experience.

Arsenic trioxide combined with all-trans retinoic acid and idarubicin significantly improved event-free survival vs ATRA and chemotherapy in patients with newly diagnosed, high-risk acute promyelocytic leukemia.

More than half of the patients included in the phase 1b BP41072 study achieved a complete response to englumafusp alfa plus glofitamab.

The FDA has approved imetelstat (Rytelo) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia requiring at least 4 red blood cell units over 8 weeks who have not responded to, or have lost response to, or are ineligible for erythropoiesis-stimulating agents.

CheckMate 77T trial saw an EFS improvement with neoadjuvant nivolumab in stage III N2 and stage III non-N2 non–small cell lung cancer.

The safety profile of zanidatamab in the HERIZON-BTC-01 trial appears to remain consistent after longer follow-up.

Continued survival was observed in dabrafenib/trametinib combination after 8 years follow-up in patients with advanced melanoma.

Despite increased education on autologous HCT, a lower rate of Black patients with multiple myeloma undergo treatment.

Investigators analyzed data from the Center for International Blood and Marrow Transplant Research who underwent autologous or allogeneic transplants.